GlaxoSmithKline PLC's $5.1bn acquisition of Tesaro Inc. sped up the company's revamp of its cancer R&D engine, but deals of that size will be outliers for now, CEO Emma Walmsley indicated on 25 September.
Speaking at the opening of a $120m biologics manufacturing and R&D facility outside Philadelphia, the exec said GSK needs to take some time to absorb the benefits Tesaro brought to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?